Vaxxinity
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Vaxxinity is a US biotechnology company founded by Lou Reese and led by CEO Mei Mei Hu, pioneering a new class of synthetic, peptide-based active immunotherapy medicines. Its platform aims to bring the efficiency of vaccines to the treatment of chronic diseases, with pipeline candidates targeting Alzheimer's, Parkinson's, migraine and hypercholesterolemia.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Vaxxinity was founded in the United States to develop peptide-based active immunotherapy medicines for chronic diseases.
- Nasdaq IPO
The company went public on Nasdaq under the ticker VAXX, listing at $16.11.
- Voluntary delisting
Vaxxinity announced its intention to voluntarily delist from Nasdaq and deregister its shares, 'going dark' to escape what the founders called an 'abusive relationship' with public markets — citing the biotech market downturn, withdrawn institutional support and dried-up liquidity — while continuing to operate privately with positive Phase 3 data, an FDA Fast Track designation for its Alzheimer's program and two new programs entering the clinic.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.